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Introduction
Hepatitis B virus infection is a disease of  global public 
health significance with about a third of  the world 
population showing evidence of  infection while about 
350 million of  these are chronically infected.[1,2] Its 
prevalence varies from one region to another resulting 
in different levels of  endemicity.[1] Prevalence may 
change over time and with the introduction of  effective 
strategies such as universal immunization. 
Nigeria which is highly endemic for hepatitis B had 
included the hepatitis B vaccine in its schedule in 1995 
but the vaccine only became widely available in 2004.
[3,4] The Nigerian hepatitis B immunization schedule 
for infants prescribes the receipt of  a birth dose, a 
second dose at six weeks and a third dose at 14 weeks 
of  life.[3]
There are various methods of  assessing the success of  
an immunization programme. 
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These include the timeliness of  receipt of  vaccines, 
the coverage of  the vaccine and measurement of  
morbidity and mortality from the target disease. 
For hepatitis B vaccine the prevalence of  acute 
hepatitis[5] complications such as hepatitis B associated 
membranous nephropathy,[6] HBsAg carrier rates[7,8] 
as well as prevalence of  hepatocellular carcinoma[7] 
have been used to assess the success of  hepatitits B 
immunization programme in various countries. 
Many countries have recorded reductions in prevalence 
of  HBsAg following the introduction of  universal 
immunization for children. These include Italy, 
Taiwan and Gambia.5,7,8In Nigeria routine coverage for 
hepatitis B has been reported [9] but few studies have 
evaluated HBsAg carrier rates since the introduction of  
hepatitis B immunization. Such studies are necessary 
to determine the effectiveness of  the programme and 
to identify problems. Such problem identification is 
important in the development of  targeted interventions 
for improvement of  the programme. In one such study 
on children in rural Nigeria that evaluated 5-7 years post 
vaccination efficacy of  hepatitis B vaccine, a significantly 
lower HBsAg carrier rate (2%) was found in immunized 
children compared to unvaccinated children (12%).[10] 
This study was however carried out in the context of  a 
project and protocols would have been strictly adhered 
to. Also the study only evaluated a narrow age range.
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Background: Nigeria commenced her hepatitis B immunization programme in 2004 but there have been few evaluations of  
the programme in different parts of  the country given the fact that prevalence in different regions of  the country varies.  The 
objective of  this study was to determine the prevalence of  HBsAg and the hepatitis B immunization status among children 
admitted to the children’s emergency room (CHER) in Benin Teaching Hospital.
Methods: A descriptive cross-sectional study carried out in 150 consecutively recruited children aged 2 months to 15 years 
admitted to the CHER of  the University of  Benin Teaching Hospital. HBsAg was assayed for in blood.
Results: HBsAg seroprevalence was 13.9%. Majority (83%) of  the children were age appropriately immunized for hepatitis 
B. Mean age at receipt of  the birth dose of  hepatitis B (28.0±20.4 days) was significantly delayed (p<0.0001). Mean age 
at completion of  the schedule(110±18.6 days) was significantly delayed compared to the recommended age of  98 days 
p<0.0002). Age, sex and socioeconomic status were not significantly associated with being seropositive(p>0,05).
Conclusion: HBsAg seroprevalence was high despite high immunization coverage. Lack of  timeliness in the receipt of  the 
birth dose and in completion of  the schedule may have contributed to the seeming lack of  effectiveness of  the immunization 
programme,
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A previous study in Benin City the study locale (20years 
ago and before the introduction of  infant immunization 
for hepatitis B) reported a prevalence of  10.8%.[11] 
There has been no prevalence study since that study. 
This study therefore set out to determine the prevalence 
of  HBsAg, and the hepatitis B vaccination status in 
children aged 2 months to 15 years admitted to the 
children’s emergency room (CHER) of  the University 
of  Benin Teaching Hospital, Benin City. 
Methodology
 This descriptive cross-sectional study was carried out 
at the CHER of  the University of  Benin Teaching 
Hospital (UBTH) between February and April 2011 in 
Edo state of  Nigeria. The UBTH is a tertiary health 
care facility which serves Edo state and receives referrals 
from its neighbouring five states.  Ethical clearance for 
the study was obtained from the UBTH ethical review 
committee. Verbal consent was obtained from parents 
of  subjects after the objectives and procedure of  the 
study had been explained to them. Assent was obtained 
from children older than 10 years.
The sample size was calculated using the 
formula:
                     n = z2pq
                             d2
where 
n =  the desired sample size
z = the standard normal deviate set at 1.96 
which corresponds to 95% confidence interval 
p = the proportion in the target population 
estimated to be positive for the hepatitis B 
surface antigen (estimated to be 10.8% using 
the prevalence found in an earlier study in Benin 
City)[11]
q = 1.0 – p
d = degree of  accuracy desired which is 0.05
This gave a sample size of  148.03 which was 
approximated to 150
All children aged between 2 months and 15 years 
admitted to CHER and whose parents gave consent were 
consecutively recruited. Children who were known to 
have Sickle Cell Anaemia.were excluded from the study. 
These children were excluded because most of  those 
that attend the CHER also attend the Sickle cell clinic 
of  the hospital which has a comprehensive package of  
care for these children, This package includes ensuring 
that the children receive hepatitis B vaccination thus 
coverage for the hepatitis B vaccination may be different 
from that of  the general population of  children.
Information on bio data such as age, sex, maternal and 
paternal educational level and occupation was obtained 
using a proforma. The proforma was pretested at the 
Institute of  Child Health Immunization clinic. The 
instrument was researcher administered. Immunization 
history was obtained for each child and parents were 
asked to bring immunization cards, from which actual 
dates of  receipt of  various doses of  the vaccine was 
obtained. In those who did not immediately have 
their immunization cards, parents were encouraged to 
bring same while the patients were visited daily until 
discharge to see if  parents would comply so that the 
actual dates of  receipt of  vaccine could be ascertained. 
Immunization could not be verified for children whose 
parents could not bring their immunization cards. 
              Socioeconomic status was determined for 
each child using the educational level and occupation of  
both parents as described by Oyedeji et al.[12]
Five (5) mls of  blood was then obtained through 
venepuncture under sterile conditions. The blood was 
spun and serum separated and then stored at -20°C 
until the time of  testing. The serum was thawed at 
room temperature and HBsAg was assayed for in the 
serum. The HBsAg was assayed for using DRG Enzyme 
linked immunosorbent assay kit by DRG International, 
inc. USA. The sensitivity of  the assay kit was 99%. To 
assess the precision and validity of  the assay kits, three 
different levels of  controls were subjected to intra and 
inter assay performance and this gave a mean percentage 
coefficient of  variation of  5%.
Data Analysis
Data was entered into a Statistical Package for Social 
Sciences (SPSS) version 13, spreadsheet. Analysis was 
done using the same soft ware and Graphpad Instat 
3. Continuous variables were presented as means 
(SD) and comparisons were done using Student t 
test. The presence of  HBsAg was reported as simple 
percentages. Association of  independent variables such 
as age, gender, socioeconomic status and immunization 
status with serostatus (the dependent variable) was 
tested using Chi Square test and Fishers Exact test as 
appropriate. Level of  significance for all tests was set at 
p<0.05 at 95% confidence interval.
Those in socioeconomic classes I-III were classified as 
high socioeconomic class while those in classes IV and 
V were classified as low socioeconomic class
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Results 
The socio-demographic characteristics of  the one 
hundred and fifty (150) children studied are shown in 
table I.
Table I Socio-demographic characteristics of  150 children and their parents
Characteristic                            n               (%)                Mean (SD)
Gender
Male                                          84                56.0                     -
Female                                       66                44.0                    -
Age group 
<1 year                                       53               35.3                     -
1-4years                                      71               47.3                    -
5-9years                                      18               12.0                    -
≥ 10years                                      8                 5.3                    -
Maternal Age
≤24                                              11                7.5                    -
25-29                                           48              32.9                    -
30-34                                           39              26.7                    -
35-39                                           31              21.2                    -
40-44                                           12                8.2                    -
≥45                                               5                 3.4                    -
Mean Age
Children (in months)               150             100.0                 33.0 (39.1)
Mothers (in years)                   146               97.3                 31.9 (5.9)   
Fathers (in years)                     136               90.7                38.9 (7.2)
Maternal LOE
I                                                  59              39.9
11                                                 9                6.1
111                                             35               23.6
IV                                               41               27.7
V                                                  4                 2.7
Socioeconomic Status
High                                           98               72.6
Low                                            37               27.4
I-university degree or equivalent, II- School certificate(Ordinary level GCE) plus teaching or other professional training III- School 
certificate or grade II teachers’ certificate or equivalents IV- modern three, primary six certificate V- Did not complete primary 
school,illiterate LOE – Level of  education
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 Figure 1 shows the hepatitis B immunization status 
of  the 146(97.3%) children for whom information 
on immunization was available. Immunization card 
was available for 41(27.3%) children. Only these 41 
were analysed for age at receipt of  the various doses 
of  the hepatitis B vaccine. The mean age at receipt of  
Hep B birth 28.3±20.4days was significantly delayed 
(p<0.0001).The mean age at receipt of  Hep B 2 
65.9±22.8 days was significantly different p<0.0001 
from the recommended age 42days (6weeks). The 
mean age at receipt of  Hep B 3 110±18.6days was 
also significantly delayed p<0.0002 compared to the 
recommended age of  98days (14weeks).
. The mean age (SD) at commencement of  immunization 
(age at receipt of  BCG, OPV0 and HepB Birth) was 
13.5(18.4) days for BCG, 9.0(12.4) days for OPV0 and 
28.3(20.4) days for Hep B Birth.  The age at receipt of  
the different vaccines recommended for receipt at birth 
is shown in table 2.
Table 3 Relationship between age, gender and socioeconomic status of  the studied children and 
their hepatitis B surface antigen status
Variable                                           HBsAg serostatus
                                                  Positive          Negative                     *p-value
                                               n       %            n         %
Age
<12months                             10    18.9        43        81.1
>12months                             11    19.6        86        80.4                          0.23        
Total                                      21                  129
Sex
Male                                       12    14.3        72        85.7          
Female                                     9     13.6       57        86.4                          1.00
Total                                       21                 129
Socioeconomic status
High                                        15   15.3          83       84.5
Low                                          6    16.2          31       83.8                         1.00
†Total                                     21                   114
* Fisher’s Exact Test
†Socioeconomic status could only be determined for 135 children
Table 2 Age at receipt of  first immunizations (BCG, OPV0 and Hep B birth)  
Age at commencement of                    BCG             OPV0           Hep B birth
Immunization (in days)                    n        %         n       %         n        %
0-7                                                  24     58.5      25    71.4      13      31.7       
8-14                                                 8      19.5        6    17.1       3         7.3
15-28                                               3        7.3        1      2.9       2         4.9 
>28                                                  6      14.7        3      8.6      23       56.1
Total                                               41    100.0      35   100.0     41      100.0
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Of  the 150 children studied 21(13.9%) were positive 
for HBsAg.  Table 3 shows the relationship between the 
age, gender and socioeconomic status of  the children 
and their HBsAg status. Of  the children aged below 
one year 10(18.9%) were positive for HBsAg while 
10(14.1%) of  those aged between 1 and 5 years were 
positive and only 1(12.5%) of  those aged ≥10years 
was positive. The association between age and HBsAg 
status was not significant p=0.23. There were 12(14.2%) 
males who were positive for HBsAg. This was not 
significantly different from 8(13.6%) females who were 
positive for HBsAg p>0.05. Of  the 98 children from 
high socioeconomic families 15(15.3%) were HBsAg 
positive and this was not significantly different from the 
6(16.2%) of  37 from low socioeconomic families.
Table 4 shows the relationship between hepatitis B 
immunization status and hepatitis B seropositivity. 
The seropositivity 15.4% among those who were fully 
immunized was not significantly different from 10.3% 
among those who had incomplete/ no hepatitis B 
immunization. p=0.77 
Table 4 Relationship between hepatitis B immunization status and Hepatitis B serostatus
Immunization status                        HBsAg Serostatus                    *pvalue
                                                          Positive           Negative
                                                       n             %            n         %
Fully immunized                             18          15.4          99       84.6  
Incomplete/ no immunization           3           10.3          26       89.7       0.77
Total                                                21                           125
*Fisher’s Exact Test
Discussion
This study has examined various aspects of  the 
hepatitis B immunization programme. The HBsAg 
seroprevalence remains high even though most of  
the children were said to be vaccinated. The HBsAg 
sero-prevalence is comparable to the findings of  an 
earlier study[11] suggesting that there may have been 
no change even with the introduction of  immunization 
programme. On the other hand it is possible that 
HBsAg may have been higher in the earlier study 
period. The possible explanation for this being that 
the higher sensitivity of  the third generation Elisa test 
used in this study compared to that used in the earlier 
study may have accounted for the seemingly higher 
prevalence in this study. In a recent review of  hepatitis 
B in Nigeria, this reason was proffered as explanation 
for the observed higher prevalence in the more recent 
studies compared to older studies.[13] It is also pertinent 
to note that the earlier study had excluded all subjects 
with possible risk factors and may thus have compared 
to this study underestimated the overall prevalence of  
hepatitis B surface antigen among children admitted to 
the children’s emergency room.
There was no significant difference in HBsAg 
seropositivity between vaccinated and incompletely/
unvaccinated children. This may have been due to few 
numbers of  the unvaccinated and also the fact that those 
who were incompletely vaccinated and those who had 
received no immunization were grouped together for 
the analysis thereby possibly confounding the results. 
This is because it has been shown that there is some 
antibody response even following a single dose of  the 
vaccine.[14,15] Also immunization in majority of  the 
children was not validated due to non availability of  
their immunization cards. It is thus possible that some 
of  those who claimed to be completely immunized may 
not have been immunized at all or were incompletely 
immunized.
The timeliness of  receipt of  the various doses was 
also examined. The marked delay in receipt of  the 
birth doses may connote ineffectiveness of  the 
programme in preventing perinatal transmission.  The 
late commencement of  hepatitis B immunization also 
meant that there would be delay in completing the 
schedule as was observed in this study. This means that 
such infants remained vulnerable for longer than usual 
and may indeed have acquired the virus during such 
extended periods of  vulnerability. The lack of  timelines 
in receipt of  birth doses and completion of  the schedule 
may have contributed to the observed lack of  effect of  
the immunization programme on seroprevalence. In 
programmes that have been successful timeliness of  
receipt of  birth doses was high.[16]
This study found age not to be significantly associated 
with hepatitis B status. This was in keeping with a study 
from Illorin.[17]Although age was not significantly 
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associated with hepatitis B in this study, most of  
the infected children were under the age of  five. In 
fact only one child older than 10 years was positive. 
This supports the fact that infections are acquired in 
childhood.  Infections acquired in childhood are more 
likely to become chronic thus it is recommended that 
the infected children be followed up. 
These findings are however different from those of  
previous studies which had shown higher prevalence 
among school age children.[18] In those studies it was 
opined that in sub-Saharan Africa, perinatal infections 
are few with rates of  infection increasing with increasing 
age reaching a peak during school years (reflecting 
horizontal transmission from child to child),[18] 
The findings in this study may suggest a change in 
epidemiology with children acquiring the infection 
earlier in childhood. This explanation is plausible as 
more children are leaving home at a younger age to 
attend day-care and pre- school facilities.
Since older children and adolescents did not benefit from 
immunization against hepatitis B in infancy it would be 
expected that they would have had a higher prevalence. 
Perhaps the fewer numbers of  children aged above five 
years in this study may be responsible for  a low relative 
contribution to the HBsAg seropositivity in this study. 
These older children who were unimmunized are likely 
to be at continued risk for hepatitis B infection. Catch-
up immunization may be recommended for this group 
of  children
The findings of  this study are at variance with other 
studies on the impact of  hepatitis B vaccination on the 
prevalence of  hepatitis B. Studies from Gambia, Taiwan 
and Italy have shown that the prevalence of  hepatitis B 
reduced following the introduction of  universal infant 
immunization[5,7,8] In these countries the coverage 
for the vaccine was high[19] unlike what is observed at 
population level in Nigeria[9] The coverage for the third 
dose of  hepatitis B vaccine in Nigeria is 27.6%[9]Thus 
even though majority of  the children studied were said 
to be immunized this may be at variance with general 
coverage in the population. This may then mean that 
population-level protection is not high contributing 
to a lack of  observed effectiveness of  hepatitis B 
immunization in this study.
A limitation of  this study is that it is a single centre study. 
The fact however that the centre is a referral centre 
means that children from the diverse geographic areas 
served by the centre are represented thus making the 
findings more generalizable. The study is also limited by 
the inability to verify the immunization status of  most 
of  the children.
In conclusion, in view of  the high prevalence of  
HBsAg in the studied children efforts at increasing the 
effectiveness of  the immunization programme should 
be made especially improving the timeliness of  receipt 
of  birth doses which was delayed in this study.
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